Patients might assess differences in clinical factors used by their physicians, such as IGF-I levels and tumor size, to seek changes in treatment, but assess differences in patient-centered concepts, such as QoL, when they consider their overall well-being. The gene discussed is IGF1; the disease is neoplasm.